Skip to main content
SpringerLink
Log in

The protein kinase 2 inhibitor CX-4945 regulates osteoclast and osteoblast differentiation In vitro

  • Research Article
  • Published:
Molecules and Cells

Abstract

Drug repositioning can identify new therapeutic applications for existing drugs, thus mitigating high R&D costs. The Protein kinase 2 (CK2) inhibitor CX-4945 regulates human cancer cell survival and angiogenesis. Here we found that CX-4945 significantly inhibited the RANKL-induced osteoclast differentiation, but enhanced the BMP2-induced osteoblast differentiation in a cell culture model. CX-4945 inhibited the RANKL-induced activation of TRAP and NFATc1 expression accompanied with suppression of Akt phosphorylation, but in contrast, it enhanced the BMP2-mediated ALP induction and MAPK ERK1/2 phosphorylation. CX-4945 is thus a novel drug candidate for bone-related disorders such as osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ahmed, K. (1999). Nuclear matrix and protein kinase CK2 signaling. Crit. Rev. Eukaryot. Gene Expr. 9, 329–336.

    Article  PubMed  CAS  Google Scholar 

  • Ahmed, K., Gerber, D.A., and Cochet, C. (2002). Joining the cell survival squad: An emerging role for protein kinase CK2. Trends Cell Biol. 12, 226–230.

    Article  PubMed  CAS  Google Scholar 

  • Allende, J.E., and Allende, C.C. (1995). Protein kinase CK2-an enzyme with multiple substrates and a puzzling regulation. FASEB J. 9, 313–323.

    PubMed  CAS  Google Scholar 

  • Asagiri, M., and Takayanagi, H. (2007). The molecular understanding of osteoclast differentiation. Bone 40, 251–264.

    Article  PubMed  CAS  Google Scholar 

  • Ashburn, T.T., and Thor, K.B. (2004). Drug repositioning: identifying and developing new uses or existing drugs. Nat. Rev. Drug Discov. 3, 673–683.

    Article  PubMed  CAS  Google Scholar 

  • Bessa, P.C., Cerqueira, M.T., Rada, T., Gomes, M.E., Neves, N.M., Nobre, A., Reis, R.L., and Casal, M. (2009). Expression, purification and osteogenic bioactivity of recombinant human BMP-4, -9, -10, -11 and -14. Protein Expr. Purif. 63, 89–94.

    Article  PubMed  CAS  Google Scholar 

  • Booth, B., and Zemmel, R. (2004). Prospects for productivity. Nat. Rev. Drug Discov. 3, 451–456.

    Article  PubMed  CAS  Google Scholar 

  • Bragdon, B., Thinakaran, S., Moseychuk, O., King, D., Young, K., Litchfield, D.W., Petersen, N.O., and Nohe, A. (2010). Casein kinase 2 beta-subunit is a regulator of bone morphogenetic protein 2 signaling. Biophys. J. 99, 897–904.

    Article  PubMed  CAS  Google Scholar 

  • Chen, D., Harris, M.A., Rossini, G., Dunstan, C.R., Dallas, S.L., Feng, J.Q., Mundy, G.R., and Harris, S.E. (1997). Bone morphogenetic protein 2 (BMP-2) enhances BMP-3, BMP-4, and bone cell differentiation marker gene expression during the induction of mineralized bone matrix formation in cultures of fetal rat calvarial osteoblasts. Calcif. Tissue Int. 60, 283–290.

    Article  PubMed  CAS  Google Scholar 

  • Choi, S.W., Son, Y.J., Yun, J.M., and Kim, S.H. (2012). Fisetin inhibits osteoclast differentiation via downregulation of p38 and c-Fos-NFATc1 signaling pathways. Evid. Based Complement Alternat. Med. 2012, 810563.

    PubMed  Google Scholar 

  • Cozza, G., Pinna, L.A., and Moro, S. (2012). Protein kinase CK2 inhibitors: a patent review. Expert Opin. Ther. Pat. 22, 1081–1097.

    Article  PubMed  CAS  Google Scholar 

  • Di Maira, G., Salvi, M., Arrigoni, G., Marin, O., Sarno, S., Brustolon, F., Pinna, L.A., and Ruzzene, M. (2005). Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ. 12, 668–677.

    Article  PubMed  Google Scholar 

  • Franceschi, R.T., and Iyer, B.S. (1992). Relationship between collagen synthesis and expression of the osteoblast phenotype in MC3T3-E1 cells. J. Bone Miner. Res. 7, 235–246.

    Article  PubMed  CAS  Google Scholar 

  • Grigoriadis, A.E., Wang, Z.Q., Cecchini, M.G., Hofstetter, W., Felix, R., Fleisch, H.A., and Wagner, E.F. (1994). c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443–448.

    Article  PubMed  CAS  Google Scholar 

  • Guerra, B., and Issinger, O.G. (1999). Protein kinase CK2 and its role in cellular proliferation, development and pathology. Electrophoresis 20, 391–408.

    Article  PubMed  CAS  Google Scholar 

  • Gyenis, L., Turowec, J.P., Bretner, M., and Litchfield, D.W. (2013). Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2. Biochim. Biophys. Acta 1834,1352–1358.

    Article  PubMed  CAS  Google Scholar 

  • Haltmaier, H.K. (1998). A Potenz aus dem Labor: Die Erektionspille VIAGRA (‘Potency from the Lab: The Erection Pill Viagra’) (Reinbek bei Hamburg, Germany: Rowohlt Taschenbuch Verlag GmbH.).

    Google Scholar 

  • Kawai, M., Bessho, K., Maruyama, H., Miyazaki, J., and Yamamoto, T. (2006). Simultaneous gene transfer of bone morphogenetic protein (BMP)-2 and BMP-7 by in vivo electroporation induces rapid bone formation and BMP-4 expression. BMC Musculoskelet. Disord. 7, 62.

    Article  PubMed  Google Scholar 

  • Kim, H.J., and Kim, S.H. (2010). Tanshinone IIA enhances BMP-2-stimulated commitment of C2C12 cells into osteoblasts via p38 activation. Amino Acids 39, 1217–1226.

    Article  PubMed  CAS  Google Scholar 

  • Kim, J., and Kim, S.H. (2012). Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond. Arch. Pharm. Res. 35, 1293–1296.

    Article  PubMed  CAS  Google Scholar 

  • Kim, K., Kim, J.H., Moon, J.B., Lee, J., Kwak, H.B., Park, Y.W., and Kim, N. (2012). The transmembrane adaptor protein, linker for activation of T cells (LAT), regulates RANKL-induced osteoclast differentiation. Mol. Cells 33, 401–406.

    Article  PubMed  CAS  Google Scholar 

  • Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 25, 402–408.

    Article  PubMed  CAS  Google Scholar 

  • Longman, R. (2004). Pharmaceutical strategies: jumpstart to products. In Vivo 22, 17.

    Google Scholar 

  • Matsuo, K., Galson, D.L., Zhao, C., Peng, L., Laplace, C., Wang, K.Z., Bachler, M.A., Amano, H., Aburatani, H., Ishikawa, H., et al. (2004). Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J. Biol. Chem. 279, 26475–26480.

    Article  PubMed  CAS  Google Scholar 

  • Moon, J.B., Kim, J.H., Kim, K., Youn, B.U., Ko, A., Lee, S.Y., and Kim, N. (2012). Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade. J. Immunol. 188, 163–169.

    Article  PubMed  CAS  Google Scholar 

  • Moseychuk, O., Akkiraju, H., Dutta, J., D’Angelo, A., Bragdon, B., Duncan, R.L., and Nohe, A. (2013). Inhibition of CK2 binding to BMPRIa induces C2C12 differentiation into osteoblasts and adipocytes. J. Cell Commun. Signal. [Epub ahead of print]

    Google Scholar 

  • Pagano, M.A., Meggio, F., Ruzzene, M., Andrzejewska, M., Kazimierczuk, Z., and Pinna, L.A. (2004). 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem. Biophys. Res. Commun. 321, 1040–1044.

    Article  PubMed  CAS  Google Scholar 

  • Pagano, M.A., Bain, J., Kazimierczuk, Z., Sarno, S., Ruzzene, M., Maira Di, G., Elliott, M., Orzeszko., A., Cozza, G., Meggiom F., et al. (2008). The selectivity of inhibitors of protein kinase CK2: an update. Biochem. J. 415, 353–365.

    Article  PubMed  CAS  Google Scholar 

  • Parvanta, C., Roth, Y., and Keller, H. (2013). Crowdsourcing 101: a few basics to make you the leader of the pack. Health Promot. Pract. 14, 163–167.

    Article  PubMed  Google Scholar 

  • Pierre, F., Chua, P.C., O’Brien, S.E., Siddiqui-Jain, A., Bourbon, P., Haddach, M., Michaux, J., Nagasawa, J., Schwaebe, M.K., Stefan, E., et al. (2011a). Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol. Cell. Biochem. 356, 37–43.

    Article  PubMed  CAS  Google Scholar 

  • Pierre, F., Chua, P.C., O’Brien, S.E., Siddiqui-Jain, A., Bourbon, P., Haddach, M., Michaux, J., Nagasawa, J., Schwaebe, M.K., Stefan, E., et al. (2011b). Discovery and SAR of 5-(3-chlorophenylamino) benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J. Med. Chem. 54, 635–654.

    Article  PubMed  CAS  Google Scholar 

  • Prudent, R., and Cochet, C. (2009). New protein kinase CK2 inhibitors: jumping out of the catalytic box. Chem. Biol. 16, 112–120.

    Article  PubMed  CAS  Google Scholar 

  • Ritt, D.A., Zhou, M., Conrads, T.P., Veenstra, T.D., Copeland, T.D., and Morrison, D.K. (2007). CK2 Is a component of the KSR1 scaffold complex that contributes to Raf kinase activation. Curr. Biol. 17, 179–184.

    Article  PubMed  CAS  Google Scholar 

  • Sarno, S., Reddy, H., Meggio, F., Ruzzene, M., Davies, S.P., Donella-Deana, A., Shugar, D., and Pinna, L.A. (2001). Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 (‘casein kinase-2’). FEBS Lett. 296, 44–48.

    Article  Google Scholar 

  • Sarno, S., Papinutto, E., Franchin, C., Bain, J., Elliott, M., Meggio, F., Kazimierczuk, Z., Orzeszko, A., Zanotti, G., Battistutta, R., et al. (2011). ATP site-directed inhibitors of protein kinase CK2: an update. Curr. Top. Med. Chem. 11, 1340–1351.

    Article  PubMed  CAS  Google Scholar 

  • Siddiqui-Jain, A., Drygin, D., Streiner, N., Chua, P., Pierre, F., O’Brien, S.E., Bliesath, J., Omori, M., Huser, N., Ho, C., et al. (2010). CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 70, 10288–10298.

    Article  PubMed  CAS  Google Scholar 

  • Son, Y.H., Song, J.S., Kim, S.H., and Kim, J. (2013). Pharmacokinetic characterization of CK2 inhibitor CX-4945. Arch. Pharm. Res. 36, 840–845.

    Article  PubMed  CAS  Google Scholar 

  • Stuart, M. (2004). Rediscovering existing drugs. Start-Up 9, 23–30.

    Google Scholar 

  • Takayanagi, H., Kim, S., Matsuo, K., Suzuki, H., Suzuki, T., Sato, K., Yokochi, T., Oda, H., Nakamura, K., Ida, N., et al. (2002). RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 416, 744–749.

    Article  PubMed  CAS  Google Scholar 

  • Zien, P., Duncan, J.S., Skierski, J., Bretner, M., Litchfield, D.W., and Shugar, D. (2005). Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2. Biochim. Biophys. Acta 1754, 271–280.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical Laboratory Science, School of Medicine, Eulji University, Daejeon, 301-746, Korea

    Jiyeon Kim

  2. Laboratory of Translational Therapeutics, Pharmacological Research Center, Bio-Organic Science Division, Korea Research Institute of Chemical Technology, Daejeon, 305-600, Korea

    You Hwa Son & Seong Hee Moon

Authors
  1. You Hwa Son
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seong Hee Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jiyeon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jiyeon Kim.

Additional information

These authors contributed equally to this work.

About this article

Cite this article

Son, Y.H., Moon, S.H. & Kim, J. The protein kinase 2 inhibitor CX-4945 regulates osteoclast and osteoblast differentiation In vitro . Mol Cells 36, 417–423 (2013). https://doi.org/10.1007/s10059-013-0184-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10059-013-0184-9

Keywords

Search

Navigation